Email this article Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
- Authors: Poddubnaya I.V.1, Baryakh E.A.2, Vorobyev V.I.3, Demina E.A.4, Zhukov N.V.5, Kaplanov K.D.6,7, Konstantinova T.S.8, Motorin D.V.9, Ptushkin V.V.10, Sarzhevsky V.O.11, Tumyan G.S.12,13
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- City Clinical Hospital №52
- Botkin Moscow City Clinical Hospital
- FSBI National Medical and Surgical Center named after N.I. Pirogova »Ministry of Health of Russia
- Federal State Budgetary Institution National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev"
- GBUZ "Volgograd Regional Clinical Oncology Center"
- FSBEI HE "Volgograd State Medical University" of the Ministry of Health of Russia
- Sverdlovsk Regional Clinical Hospital No. 1
- National Medical Research Center named after V.A. Almazov» Ministry of Health of Russia
- City Clinical Hospital named after S.P. Botkin
- Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University named after N.I. Pirogov» Ministry of Health of Russia
- FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
- FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
- Issue: Vol 22, No 2 (2020)
- Pages: 52-55
- Section: Conference Proceedings
- URL: https://journals.rcsi.science/1815-1434/article/view/34878
- DOI: https://doi.org/10.26442/18151434.2020.2.200206
- ID: 34878
Cite item
Full Text
Abstract
Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged >60 years, with the presence of ≥3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkin’s lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant.
Aim. To change and adapt current treatment approaches in the current epidemiological environment.
Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Irina V. Poddubnaya
Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: ivprectorat@inbox.ru
ORCID iD: 0000-0002-0995-1801
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowElena A. Baryakh
City Clinical Hospital №52
Email: ebaryakh@gmail.com
ORCID iD: 0000-0001-6880-9269
Cand. Sci. (Med.)
Russian Federation, MoscowVladimir I. Vorobyev
Botkin Moscow City Clinical Hospital
Email: morela@mail.ru
Ph.D., hematologist of hematology department No. 6
Russian Federation, MoscowE. A. Demina
FSBI National Medical and Surgical Center named after N.I. Pirogova »Ministry of Health of Russia
Email: or@hpmp.ru
Dr. med. sciences, prof., prof. cafe Hematology and Cell Therapy Institute for Advanced Medical Studies, Member of the Board of the Russian Society of Oncohematologists
Russian Federation, MoscowNikolay V. Zhukov
Federal State Budgetary Institution National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev"
Email: or@hpmp.ru
Dr. med. sciences, head. Dep. Interdisciplinary Oncology
Russian Federation, MoscowK. D. Kaplanov
GBUZ "Volgograd Regional Clinical Oncology Center"; FSBEI HE "Volgograd State Medical University" of the Ministry of Health of Russia
Email: or@hpmp.ru
Cand. med. sciences, head. Department of Hematology, Assistant oncology with a course of oncology and hematology FUV, member of the Russian Society of Oncohematologists and the National Hematology Society
Russian Federation, VolgogradT. S. Konstantinova
Sverdlovsk Regional Clinical Hospital No. 1
Email: or@hpmp.ru
Cand. med. sciences, head. Department of Hematology, hematologist of the highest category, chapters. Freelance hematologist of the Ural Federal District and the Ministry of Health of the Sverdlovsk Region
Russian Federation, YekaterinburgDmitry V. Motorin
National Medical Research Center named after V.A. Almazov» Ministry of Health of Russia
Email: or@hpmp.ru
Cand. Med. Sciences, Department of Chemotherapy of Oncohematological Diseases and Bone Marrow Transplantation No. 2
Russian Federation, St. PetersburgV. V. Ptushkin
City Clinical Hospital named after S.P. Botkin
Email: or@hpmp.ru
Dr. med. sciences, prof., deputy chapters. hematology doctor, chapters. Freelance specialist-hematologist of the Moscow Department of Health, member of the National Hematology Society and the Russian Society of Oncohematologists
Russian Federation, MoscowVladislav O. Sarzhevsky
Federal State Autonomous Educational Institution of Higher Education “Russian National Research Medical University named after N.I. Pirogov» Ministry of Health of Russia
Email: or@hpmp.ru
Dr. med. sciences, prof. cafe Hematology and Cell Therapy Institute for Advanced Medical Studies
Russian Federation, MoscowG. S. Tumyan
FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia; FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
Email: or@hpmp.ru
Dr. med. sciences, prof., prof. cafe oncology and palliative medicine, Vedas. scientific al. Hemoblastosis chemotherapy department, member of the board of the Russian Society of Oncohematologists
Russian Federation, MoscowReferences
- https://www.worldometers.info/coronavirus/
- https://www.cdc.gov/coronavirus/2019-ncov/
- https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma
- https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematological-malignancies-hodgkin-lymphoma-in-the-covid-19-era/
- Liang W et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21 (3): 335–7. doi: 10.1016/S1470-2045(20)30096-6
- Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020; 32 3(18): 1775–6. doi: 10.1001/jama.2020.4683
- Lambertini M, Toss A, Passaro A et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’perspective. ESMO Open 2020; 5: e000759. doi: 10.1136/esmoopen-2020-000759
- Hanna TP, Evans GA, Booth CM et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020; 17: 268–70.
- Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 2020; 0(0): imt-2020-0067. doi: 10.2217/imt-2020-0067
- https://clinicaltrials.gov/ct2/show/NCT03474133?term=basalt&draw=2&rank=1
